

Date: 13.02.2019

To,

The Manager
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001

Dear Sir/Madam,

Sub: Outcome of Board meeting under regulation 30 read Schedule III of SEBI (Listing Obligations and Disclosure requirements) regulations, 2015

Ref:Sangam Health Care Products Limited (Scrip Code: 531625)

With reference to the subject cited, this is to inform the Exchange that at the Board meeting of Sangam Health Care Products Limited held on Wednesday, the 13th day of February at 04.00 P.M. at the registered office of the Company the following were duly considered and approved by the Board:

1. Un-audited Financial Results for the quarter ended 31.12.2018
2. Limited Review Report for the quarter ended 31.12.2018.

The meeting concluded at 05.30 P.M.

This is for the information and records of the Exchange, please.

Thanking you.

Yours faithfully,
For Sangam Health Care Products Limited


A.Bala Gopal
Managing Director
(DIN: 01702903)



SANGAM HEALTH CARE PRODUCTS LIMITED
205 & 206, AMARCHAND SHARMA COMPLEX, S.P. ROAD, SECUNDERABAD
CIN : L24230TG1993PLCO16731 Website: www.sangamhealthcare.co.in Email: sangamlisting@gmail.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTH ENDED 31-12-2018

(Rs. In Lakhs)

S.No.	Particulars	QUARTER ENDED			NINE MONTHS ENDED		YEAR ENDED
		31/12/2018	30/09/2018	31/12/2017	31/12/2018	31/12/2017	31/03/2018
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	REVENUE FROM OPERATIONS						
(a)	Revenue from Operations	515.30	601.05	656.06	1,620.46	1,610.46	2,088.90
(b)	other income	0.00	0.00	0.50	0.00	0.50	1,841.02
2	Total Income/Revenue	515.30	601.05	656.56	1,620.46	1,610.96	3,929.92
3	Expenditure						
(a)	Cost of material consumed	248.00	301.07	393.38	837.09	833.19	1,177.57
(b)	Purchase of stocks in Trade,				0.00		
(c)	changes in inventories of finished goods, work in process and stok in trade	(73.28)	14.90	(71.34)	(73.38)	(39.95)	327.66
(d)	employee benefit exp	114.59	125.17	124.68	369.78	345.91	480.16
(e)	Financial cost	103.64	62.44	101.35	103.64	320.20	332.94
(f)	Depreciation and amolgation exp	37.98	38.07	37.85	114.12	114.13	152.28
(g)	other exp	98.94	113.99	93.49	447.82	306.26	566.30
4	Total Expenses	529.87	655.64	679.41	1,799.07	1,879.74	3,036.91
5	Profit/(Loss) before expectional items, tax	(14.57)	(54.59)	(22.85)	(178.61)	(268.78)	893.01
6	Expectional items	0.00	0.00	0.00	0.00	0.00	0.00
7	Profit/(Loss) before Tax	(14.57)	(54.59)	(22.85)	(178.61)	(268.78)	893.01
8	Tax expenses current tax differed tax						7.36 148.28
9	Profit/(Loss) for the period from continueing operations	(14.57)	(54.59)	(22.85)	(178.61)	(268.78)	737.37
10	Profit /Loss from discontinued	0.00	0.00	0.00	0.00	0.00	0.00
11	Tax expenses from discontinued operations	(14.57)	(54.59)	(22.85)	(178.61)	(268.78)	737.37
12	Profit/loss for the period	(14.57)	(54.59)	(22.85)	(178.61)	(268.78)	737.37
13	Other Comprehensive income	NIL	NIL	NIL	NIL	NIL	NIL
(a)	Item that will not be reclassified to profit or loss						
(b)	Tax relating to items that will not be reclassified to profit or loss						
(c)	Item. that will be reclasified to profit or loss						
(d)	Tax relating to items that will be reclassified to profit or loss						
	Total Comprehensive Income for the period						
14	Profit/Loss for the period after comprehensive income	(14.57)	(54.59)	(22.85)	(178.61)	(268.78)	737.37
15	Paid up Equity Share Capital (Face Value Rs.10/- per share	1,486.07	1,486.07	1,486.07	1,486.07	1,486.07	1,486.07
17	Earning per Share						
	Basic	(0.08)	(0.36)	(0.15)	(0.85)	(1.81)	(4.63)
	Diluted	(0.08)	(0.36)	(0.15)	(0.85)	(1.81)	(4.63)

Note :

- 1 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at the meeting held on 13.02.2019
- 2 The Segment reporting as defined in Accounting Standard-17 is not applicable, as the operation of the Company are related to one Segment
- 3 Previous Accounting period's figures have been grouped/regrouped wherever considered necessary.
- 4 Prersuant to the enactment of the Companies Act 2013 (The Act the Company has effective,, 1st April, 2014 reviewed & revised the estimated useful lives of its fixed assets, generally in accordance with the provision of the Schedule II to the Act. The consequential impact (after considering the transaction provision specified in Schedule II) on the depreciation charges & on the result for the quarter is not material.
- 5 The Statutory Auditors have carried out a limited review report of the financial results for the quarter ended 31.12.2018, in accordance with Regulation 33 of SEBI(LODR)Regulations. 2015.

Place : Secunderabad
Date : 13.02.2019

By order of the Board
For SANGAM HEALTH CARE PRODUCTS LIMITED
A. B. S. Reddy
MANAGING DIRECTOR





LIMITED REVIEW REPORT


To.
The Board of Directors.
Sangam Health Care Products limited

We have reviewed the accompanying statement of unaudited financial results of Sangam Health Care Product Limited, Secunderabad for the quarter and Nine months ended 31st December, 2018. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors of the Company. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410. "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express any audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Accounting Standards specified under section 133 of the Companies Act, 2013 read with Rule 7 of the Companies (Accounts) Rules, 2004 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For K.R.Shekher & Co.,
Chartered Accountants
FRN : 010828S



Rajashekhar Kaparti
Partner
Membership No. 214810

Place: Hyderabad
Date: 13/02/2019